Skip to content
Clinical Trials – home
VerifiedinfoResponsive

Studienzentrum Dr. Beate Schwarz

Germany Bismarkstrasse 49, 89129 Langenau, Germany

  • 5 trials recruiting
  • Psoriasis · Hidradenitis · Chronic spontaneous urticaria
  • Adults and children

About Specializations

Studienzentrum Dr. Beate Schwarz in Langenau, Germany specialises in clinical trials of conditions such as Psoriasis, Hidradenitis, Chronic spontaneous urticaria, Psoriatic arthropathy, and other specialisations. This site conducts important research.

Main research areas of the site

Skin and Connective Tissue Diseases

At Studienzentrum Dr. Beate Schwarz in Langenau, much of the research focuses on dermatology, especially psoriasis, atopic dermatitis, acne, rosacea, and skin ulcers. These studies are designed to test new treatments, compare them with current options, and better understand how to improve symptom control and skin healing.

  • Moderate-to-severe plaque psoriasis and related inflammatory skin disease
  • Atopic dermatitis, nummular dermatitis, and other eczema conditions
  • Hidradenitis suppurativa and chronic venous ulcers
  • Acne, rosacea, actinic keratosis, and candidiasis of the skin

The site is actively involved in evaluating therapies that may reduce inflammation, relieve itch, support wound closure, and improve day-to-day quality of life for people with chronic skin diseases.

Immune System Diseases

Another major area of research at this health care site is immune-mediated disease, with trials centered on conditions such as chronic spontaneous urticaria, psoriatic arthritis, and severe forms of atopic dermatitis. The goal is to assess whether new therapies can more effectively control immune-driven symptoms and improve patient outcomes.

  • Chronic spontaneous urticaria and itch-related disease
  • Active psoriatic arthritis
  • Moderate-to-severe atopic dermatitis
  • Immune-related inflammation linked to chronic skin disorders

These trials commonly compare emerging treatments with placebo or existing care to better define treatment effectiveness and safety in immune system diseases.

Nervous System Diseases

The research portfolio also includes studies in nervous system diseases, particularly conditions where nerve-related symptoms such as persistent itch play an important role. This includes work on notalgia paresthetica, where investigators are exploring whether new therapies can reduce discomfort and improve symptom control.

  • Moderate-to-severe pruritus associated with notalgia paresthetica
  • Persistent itch and sensory symptoms affecting daily comfort
  • Symptom relief in chronic neurocutaneous conditions

These studies aim to improve understanding of difficult-to-treat itch and to identify better ways to manage long-lasting nerve-related skin symptoms.

Parasitic Diseases

Research at the site also covers parasitic diseases, including scabies, a contagious skin condition that causes intense itching and irritation. The trials in this area focus on evaluating treatment effectiveness and confirming that new or existing therapies can clear infection-related skin symptoms.

  • Scabies treatment and symptom resolution
  • Clinical response after topical therapy
  • Improving control of itch and skin irritation caused by infestation

These studies are intended to support better treatment choices for patients affected by parasitic skin infections.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Bismarkstrasse 4989129 LangenauGermany
Recruiting now
5 trials
Conditions studied
10
Partner status
Verified

More sites in LangenauGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

20 clinical trials

Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Jnj-77242113
  • Sponsor:Janssen Cilag International
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivermectin
  • Sponsor:Dermapharm AG
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camellia Sinensis (Green Tea) Leaf Extract
  • Sponsor:Aresus Pharma GmbH
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Janssen Cilag International
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Jnj-77242113
  • Sponsor:Janssen Cilag International
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Janssen Cilag International
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Alumis Inc.
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Jnj-81241459
  • Sponsor:Janssen Cilag International
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).